Thalia Therapeutics enters new phase of development

(Sharecast News) - Thalia Therapeutics said on Friday that it was entering a new phase of development ahead of its annual general meeting, with the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75m fundraising expected to accelerate its transition into a clinical-stage RNA therapeutics company. Subject to shareholder approval, the deal will add miRisten, a Phase 1 microRNA treatment for acute myeloid leukaemia, to the group's pipeline alongside its Nuvec delivery technology and cardiovascular siRNA programme.

The AIM-traded company said the fundraising provides sufficient capital to complete the ongoing Phase 1 study of miRisten, with topline data expected in the first half of 2027, while also advancing its cardiovascular programme towards IND-enabling studies and further developing the Nuvec platform.

Thalia said the expanded portfolio would strengthen its position in oncology and cardiovascular disease, targeting large unmet medical needs.

At 0834 BST, shares in Thalia Therapeutics were down 7.69% at 0.6p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate